StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Aggregate of 9 sell-side ratings as of 2026-05-01. Stonvex does not endorse these ratings.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $7.87 | $7.83 | -0.51% | 0.1M |
| 05-19 | $7.74 | $7.60 | -1.81% | 0.1M |
| 05-20 | $7.83 | $7.87 | +0.51% | 0.1M |
| 05-21 | $7.85 | $7.82 | -0.38% | 0.0M |
| 05-22 | $7.86 | $7.83 | -0.38% | 0.1M |
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Next report date, year-over-year trend, and recent quarter history.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows KMDA's percentile within the scored universe — observational ranking, not a recommendation.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.